Takeda Pharmaceutical Co Lowers FY2026 Adj EPS Guidance from $3.01 to $2.96 vs $1.57 Est; Lowers FY2026 Sales Guidance from $29.585B to $29.116B vs $28.950B Est
Takeda Pharmaceutical Co (NYSE:TAK) lowers FY2026 Adj EPS guidance from $3.01 to $2.96 vs $1.57 analyst estimate. Lowers FY2026 sales outlook from $29.585 billion to $29.116 billion vs $28.950 billion estimate.
Takeda slightly lowered its money-making forecast for next year, but it's still expecting to earn more and sell more than what experts predicted. Think of it like a student saying "I'll get an A-minus instead of an A" — still really good, just a tiny bit less impressive than before.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.